Medtronic & Fitbit Partner on New CGM Solution for Simplified Type 2 Diabetes Management

Medtronic plc, the global developer of medical technology, and Fitbit, a strong player in the connected health and fitness market, announced a partnership to integrate health and activity tracking for patients living with diabetes and their physicians and care teams. The iPro2 myLog mobile app will allow patients living with type 2 diabetes to see their glucose levels and physical activity data in one streamlined application. The new integration and partnership brings together Medtronic’s sophisticated medical technology with the convenience of automatic activity tracking from Fitbit, which provides meaningful insights into how exercise impacts glucose levels for more effective diabetes care management.
 
“We believe monitoring glucose is a critical element in the management of diabetes and therefore, glucose should be included among other vital signs. As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the United States,” said Laura Stoltenberg, vice president and general manager of Non-Intensive Diabetes Therapies at Medtronic. “By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimize therapy and patients can better understand how to manage their diabetes. By helping people with diabetes implement lasting lifestyle changes, this partnership underscores our commitment to transforming diabetes care, together, for greater freedom and better health.”
 
Maintaining and tracking glucose levels is critical to effectively managing diabetes. For people living with type 2 diabetes, understanding how exercise affects glucose levels is a critical element to proper glucose management and long-term health. Additionally, many patients are manually tracking and recording their physical activity, requiring them to recall and communicate that information to their physician from memory. The iPro2 myLog mobile app will allow type 2 diabetes patients to easily combine data generated by their Fitbit activity tracker and Medtronic’s iPro2 professional CGM system, eliminating the need to enter physical activity data manually, and providing a clear understanding of how exercise impacts glucose levels. MyLog will simplify the sharing of information with a patient’s healthcare team, facilitating productive discussions about care and the benefits of exercise on diabetes management.
 
“We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient’s physical activity,” said Adam Pellegrini, vice president of Digital Health for Fitbit. “By partnering with Medtronic, we are able to bring the power of Fitbit’s automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation.”